TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Identifying Factors That Predict Antidepressant Treatment Response

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Current DSM-IV diagnosis of major depressive episode, as determined by Structured Clinical Interview for DSM-IV (SCID-IV)~* Primary diagnosis of MDD, based on prominence of symptoms and target for intervention (comorbid anxiety disorders, except obsessive-compulsive disorder (OCD), will not be criteria for exclusion)~* Score of at least 18 on the 17-item Hamilton Rating Scale for Depression (HAM-D17)~* Agrees to use an effective form of contraception and/or double barrier method~Exclusion Criteria:~* Previously treated for major depression with either medication or psychotherapy~* Current psychosis, dementia, eating disorder, or dissociative disorder~* History of bipolar disorder (I and II) or schizophrenia~* Alcohol or drug dependence within 3 months prior to study entry or current alcohol or drug abuse (excluding nicotine and caffeine), as assessed by medical history and urine drug screening~* Requires neuroleptic or mood stabilizer therapy in addition to depression treatment~* Presence of any acute or chronic medical disorder that could affect successful completion of the trial~* Medical contraindications that would preclude treatment with escitalopram or duloxetine~* Presence of practical issues that would likely prevent completion of the study (e.g., planned geographical relocation)~* Pregnant or breastfeeding~* Medical conditions that could prevent the safe use of MRI (e.g., pacemaker, aneurysm clips, neurostimulators, cochlear implants, metal in eyes, or other implants; steel worker)~* Medical conditions that could prevent the safe completion of a dexamethasone-corticotropin releasing factor (Dex-CRF) test (e.g., uncontrolled hypertension, significant abnormalities in EKG, anemia, known allergies against drugs)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Escitalopram (Type: ACTIVE_COMPARATOR): Participants will receive treatment with escitalopram for 12 weeks
- Duloxetine (Type: ACTIVE_COMPARATOR): Participants will receive treatment with duloxetine for 12 weeks
- CBT (Type: ACTIVE_COMPARATOR): Participants will receive 16 one-hour sessions of cognitive behavioral therapy delivered over 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HIV Non Occupational Post-Exposure Prophylaxis (PEP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* HIV uninfected on the basis of a negative HIV Rapid Test, EIA or Western blot, and a negative HIV-1 RNA assay~* Possible non-occupational exposure to HIV-1, recent enough to permit receiving the first dose of study medication within 72 hours from the end of the exposure.~* Able to understand the study procedures and willing to sign informed consent~Exclusion Criteria:~* Any active psychiatric illness or active drug or alcohol abuse that, in the opinion of the investigator, could prevent compliance with study procedures.~* Pregnancy.~* Chronic hepatitis B infection, diagnosed by either positive serum HBsAg or positive serum HBV DNA; or prior lamivudine therapy for hepatitis B.~* Creatinine clearance less than 50 mL/min as calculated by Cockcroft-Gault formula.~* Unwillingness to participate in study procedures, including Mental Health referral and intervention.~* Known intolerance or allergy to tenofovir DF, emtricitabine or raltegravir.~* Use of prohibited concomitant medication: dilantin, phenobarbital and rifampin which cannot be used with raltegravir.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1 (Type: OTHER): TRUVADA

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tolcapone Treatment of Pathological Gambling

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women age 21-75;~2. Meet diagnostic criteria for current pathological gambling based on DSM-IV criteria and confirmed using the clinician-administered Structured Clinical Interview for Pathological Gambling (SCI-PG) (Grant et al., 2004);~3. Gambling behavior within 2 weeks prior to enrollment;~4. Women of child bearing age are required to have a negative result on a beta-human chorionic gonadotropin pregnancy test;~5. Women of childbearing potential utilizing a medically accepted form of contraception defined as double barrier, oral contraceptive, injectable contraceptive, implantable contraceptive devices, and abstinence.~Exclusion Criteria:~1. Infrequent gambling (i.e. less than one time per week) that does not meet DSM-IV criteria for PG;~2. Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen as determined by the investigator;~3. History of elevated liver enzymes (AST/ALT) or other liver abnormalities;~4. History of seizures;~5. Myocardial infarction within 6 months;~6. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;~7. A need for medication other than tolcapone with possible psychotropic effects or unfavorable interactions as determined by the investigator;~8. Clinically significant suicidality (defined as score 2 or higher on HAM-D item 3);~9. Current co-morbid Axis I disorder determined by the Structured Clinical Interview for DSM-IV (SCID), (First et al., 1995) - except for nicotine dependence;~10. Lifetime history of bipolar disorder type I or II, schizophrenia, or any psychotic disorder determined by SCID;~11. Clinically significant cognitive impairment (defined as score less than 88 on 3MS);~12. Current or recent (past 3 months) DSM-IV substance abuse or dependence;~13. Positive urine drug screen at screening;~14. Initiation of psychotherapy or behavior therapy for pathological gambling within 3 months prior to study baseline;~15. Previous treatment with tolcapone;~16. Treatment with an investigational medication or depot neuroleptics within 3 months;~17. Refusal to sign the tolcapone information sheet.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tolcapone (Type: EXPERIMENTAL): Tolcapone 100-300mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brain Imaging Techniques That Predict Antidepressant Responsiveness

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Intervention Group:~  * Right-handed,~ * Be able to lie still on their back for about 120 minutes,~ * Meet DSM-IV criteria for major depression (single or recurrent),~ * Have had depressive symptoms for at least 1 month prior to screen visit,~ * Must score an 18 or above on the Hamilton-D at both the initial screening visit and first fMRI scanning session,~ * Able to understand and speak English.~* Control Group: same as above with the exception of no diagnosis of psychiatric disorder.~Exclusion Criteria:~* Any history of seizures,~* Current medical disorders that might make interpretation of scan data difficult,~* Diabetes requiring insulin treatment,~* A serious heart disorder or subjects who have had a heart attack within the last 3 months,~* Subjects who meet DSM-IV criteria for alcohol/drug abuse or dependence within the last six months,~* Other current DSM-IV Axis I or Axis II diagnoses,~* A personal or family history of bipolar disorder,~* Current use of medication that affects central nervous system (CNS) function,~* Participation in the last 30 days in a clinical study involving an investigational drug,~* A subject with metallic implants, such as prostheses, shrapnel or aneurysm clip-S, or persons with electronic implants, such as cardiac pacemakers. The magnetic field generated by the MRI machine can cause a displacement or malfunctioning of these devices.~* A subject who is claustrophobic,~* Female subjects who are pregnant,~* A subject at serious risk for suicide,~* Diagnosis of cancer in the past 3 years and/or has active neoplastic disease,~* Nonresponse to 2 adequate trials of antidepressant treatment,~* Nonresponse to 2 adequate trials of an empirically supported psychotherapy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Depressed; Venlafaxine treatment (Type: ACTIVE_COMPARATOR): Currently depressed subjects; Randomized medication treatment with Venlafaxine extended release tablets (Venlafaxine ERT). Dosage 75-300mg/day for up to 6 months.
- Depressed; Fluoxetine treatment (Type: ACTIVE_COMPARATOR): Currently depressed subjects; Randomized medication treatment with Fluoxetine tablets. Dosage 20-80mg/day for up to 6 months.
- Control (Type: NO_INTERVENTION): Non-psychiatric subjects with no past or current history of depression. Subjects will receive no medication

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Ranibizumab on Malignant Conjunctival Neoplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Ability to provide written informed consent and comply with study assessments for the full duration of the study~* Age \> 21 years~* Tumors whose treatment with standard therapy would cause significant visual morbidity~* Diagnosis of biopsy proven malignant conjunctival neoplasia and are~* Recurrent disease~* Multi-focal disease~* Diffuse disease~Exclusion Criteria:~* Extension of tumor into eye or orbit.~* Regional spread or metastatic disease~* Pregnancy (positive pregnancy test) or lactation.~* Premenopausal women not using adequate contraception. The following are considered effective means of contraception: surgical sterilization or use of oral contraceptives, barrier contraception with either a condom or diaphragm in conjunction with spermicidal gel, an IUD, or contraceptive hormone implant or patch.~* Current infection or inflammation in either eye~* Any other condition that the investigator believes would pose a significant hazard to the subject if the investigational therapy were initiated~* Participation in another simultaneous medical investigation or trial

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Subconjunctival ranibizumab (Type: EXPERIMENTAL): Patients will receive subconjunctival ranibizumab every 2-4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Worksite Phone Counseling for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Smoking employee or spouse in contemplation, action, or recently entering maintenance stage of change~* English speaking~Exclusion Criteria:~* Smoker in precontemplation stage of change

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Directive (Type: ACTIVE_COMPARATOR): Participants receive up to 7 directive smoking cessation coaching telephone calls from the quitline over 9 weeks.
- Nondirective (Type: EXPERIMENTAL): Participants receive up to 7 nondirective smoking cessation coaching telephone calls from the quitline over 9 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Long-term Safety and Clinical Activity of Givosiran (ALN-AS1) in Patient With Acute Intermittent Porphyria (AIP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed participation in Part C of study ALN-AS1-001 (NCT02452372)~* Not on a scheduled regimen of hemin~* Women of child bearing potential must have a negative serum pregnancy test, not be nursing, and use acceptable contraception~* Willing and able to comply with the study requirements and to provide written informed consent~Exclusion Criteria:~* Clinically significant abnormal laboratory results~* Received an investigational agent (other than ALN-AS1) within 90 days before the first dose of study drug or are in follow-up of another clinical study~* History of multiple drug allergies or intolerance to subcutaneous injection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Givosiran (Type: EXPERIMENTAL): At the beginning of this study, participants received either givosiran 2.5 mg/kg subcutaneous (SC) injection once monthly(QM), givosiran 5.0 mg/kg SC injection QM, or givosiran 5.0 mg/kg SC injection once every 3 months (Q3M). Within a year, all participants were transitioned to givosiran 2.5 mg/kg SC injection QM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Novel Compositions for Treating or Preventing Dermal Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy adults~Exclusion Criteria:~* Individuals with any chronic disease will be excluded from the study including those with the following conditions:~  * Diabetes~ * Any type of Malignancy~ * Severe coronary artery disease~ * HIV infection~ * Hepatitis C or B~ * Any sign of skin disorder or disease aside from normal aging, dermal atrophy, or seborrheic keratoses.~ * Premenopausal women will be excluded~ * Patients taking the following medications will be excluded:~ * Cyclosporin~ * Calcium channel blockers: diltiazem, verapamil~ * Antifungal agents e.g. clotrimazole, fluconazole, itraconazole~ * Antibiotics: clarithromycin, erythromycin, rifampicin~ * Anticonvulsants: carbamazepine, phenobarbitone, phenytoin~ * Antinausea drugs e.g. metoclopramide~ * Other drugs e.g. danazol, protease inhibitors (e.g. for HIV and hepatitis C including ritonavir, indinavir, boceprevir, and telaprevir)~ * Grapefruit juice~ * St John's wort (Hypericum perforatum, hypericin)

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 100 Years
- Healthy Volunteers: t

Study Arms:
- Rapamycin (Type: EXPERIMENTAL): Rapamycin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Autologous Fibroblasts in the Treatment of Severe Facial Acne Scarring

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female, between 18 years and 65 years of age.~2. Investigator assessment of the acne scarring on each cheek of moderate to severe.~3. A history of acne scarring for more than 3 years.~4. Subject assesses the appearance of both sides of their facial acne scars as dissatisfied or very dissatisfied with appearance.~Exclusion Criteria:~1. Significant active acne.~2. Use of oral antibiotic or retinoid active acne therapy within one year of enrollment.~3. Presence of hypertrophic scars on the cheeks.~4. More than 20% of treatment area comprised of ice pick scars or sinus tracts~5. Treatment area per cheek is less than 9 cm x cm~6. Unilateral or unbalanced acne scar distribution.~7. Physical attributes which prevent the assessment or treatment of the acne scars.~8. Treatment with an investigational product or procedure within 30 days prior to study enrollment or plans to participate in another clinical trial during the course of this study.~9. Previous treatment with Isolagen TherapyTM.~10. Use of Isotretinoin within one year of enrollment into study.~11. Use of permanent or semi-permanent dermal fillers in the treatment areas within defined time frames.~12. Disorders or drugs that increase bleeding or clotting.~13. Pregnant or lactating women or women trying to become pregnant during the study.~14. Excessive exposure to sun.~15. Smoking more than ½ pack of cigarettes per day.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Double blinded active (Type: EXPERIMENTAL): Subject will receive autologous fibroblast treatment on either their left or right side of their face
- Double blinded placebo (Type: PLACEBO_COMPARATOR): Subject will receive placebo treatment on the opposite side of the face from active treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female at least 9 years of age and older.~* Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit).~* Subject must have an Evaluator's Global Severity Score (EGSS) of 3 (moderate) or 4 (severe) at the baseline visit.~* Subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 30, but no more than 100.~* Subjects with a facial acne non-inflammatory lesion (open and closed comedones) count no less than 35, but no more than 150.~* Subjects with 2 or fewer facial nodules.~Exclusion Criteria:~* Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram negative folliculitis, dermatitis, eczema.~* Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.~* Subjects with more than 2 facial nodules.~* Female subjects who are pregnant, nursing mothers, planning a pregnancy during the course of the study, or become pregnant during the study.~* Use of estrogens (eg, Depogen, Depo-Testadiol, Gynogen, Valergen, etc) for less than 12 weeks immediately preceding study entry; subjects treated with estrogens 12 or more consecutive weeks immediately prior to study entry need not be excluded unless the subject expects to change dose, drug or discontinue estrogen use during the study.~* Treatment of any type of cancer within the last 6 months, with the exception of complete surgical excision of skin cancer outside the treatment area.~* Subjects who have not undergone specified washout period(s) for topical preparations/physical treatments used on the face or subjects who require the concurrent use in the treatment area.~* Subjects who have not undergone specified washout period(s) for systemic medications or subjects who require the concurrent use of systemic medications.~* Subjects with any underlying disease that the investigator deems uncontrolled, and poses a concern for the subject's safety while participating in the study.

- Gender: ALL
- Minimum Age: 9 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDP-126 Gel (Type: EXPERIMENTAL): None
- IDP-126 Vehicle Gel (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete